MediciNova Inc was incorporated in the State of Delaware on September 2000.It is a biopharmaceutical company focused on developing novel, small molecule therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the U.S. market. The Company operates in a single industry segment - the discovery and development of small molecule therapeutics. Its core programs includes, MN-001 (NASH), MN-166 (Neurology Diseases) and MN-221 (Respiratory Diseases). Its non-core programs include, MN-001 (Bronchial Asthma), MN-001 (Interstitial Cystitis), MN-029 (Cancer) and MN-221 (Preterm Labor). The Company is subject to government regulations, in the U.S., the FDA, under the Federal Food, Drug and Cosmetic Act, as amended, and other federal statutes and regulations.